Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia
Open Access
- 30 August 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 10, 633
Abstract
Risperidone has been used to treat the symptoms of schizophrenia and to reduce its relapse. However, the responses to treatment show great variability among patients. The potassium channel has been reported as an effective target for antipsychotics. KCNH7, a member of the voltage-gated K+ channel Kv11 family, is primarily expressed in the brain. Here, we assessed the genetic association of KCNH7 with risperidone responses in 393 schizophrenia patients. The patients were treated with risperidone for 6 weeks. The reduction rates of Positive and Negative Syndrome Scale (PANSS) scores were determined to quantify drug response. We also examined the associations between six single-nucleotide polymorphisms (SNPs) of KCNH7 and the risperidone responses for a total of 6 weeks. The SNP rs77699177 (C > T) in the KCNH7 gene intron was significantly associated with the treatment response reflected by the PANSS reduction rate (CC, 55.8 ± 23.0; TC, 70.9 ± 20.3, P = 0.000110), indicating that patients with the TC genotype have better efficacy for antipsychotic therapy. The rs2241240 SNP also showed a significant association with treatment responses after 6 weeks of treatment (P = 0.00256). The findings indicate that the voltage-gated K+ channel KCNH7 is a potential functional marker for the identification of the response to risperidone treatment in schizophrenia patients. Note: The study was registered under clinical trial number ChiCTR-RNC-09000522 (http://www.chictr.org/).Keywords
This publication has 34 references indexed in Scilit:
- Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010The British Journal of Psychiatry, 2012
- Transcranial stimulation in depressionThe British Journal of Psychiatry, 2012
- TheKCNH2gene is associated with neurocognition and the risk of schizophreniaThe World Journal of Biological Psychiatry, 2011
- Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opinion on Drug Metabolism & Toxicology, 2010
- Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control studyBehavioral and Brain Functions, 2010
- Should the PANSS Be Rescaled?Schizophrenia Bulletin, 2009
- Genome-wide pharmacogenomic analysis of response to treatment with antipsychoticsMolecular Psychiatry, 2009
- A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophreniaNature Medicine, 2009
- Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescentsPharmacogenetics and Genomics, 2009
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007